These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35999133)

  • 1. Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with "no-option" critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial.
    Mohamed SA; Duffy A; McInerney V; Krawczyk J; Hayat A; Naughton S; Finnerty A; Holohan M; Liew A; Tubassam M; Walsh SR; O'Brien T; Howard L
    Cytotherapy; 2022 Dec; 24(12):1259-1267. PubMed ID: 35999133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous bone marrow mesenchymal stromal cell therapy for "no-option" critical limb ischemia is limited by karyotype abnormalities.
    Mohamed SA; Howard L; McInerney V; Hayat A; Krawczyk J; Naughton S; Finnerty A; Holohan M; Duffy A; Moloney T; Kavanagh E; Burke P; Liew A; Tubassam M; Walsh SR; O'Brien T
    Cytotherapy; 2020 Jun; 22(6):313-321. PubMed ID: 32273232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion and angiogenic potential of mesenchymal stem cells from patients with critical limb ischemia.
    Brewster L; Robinson S; Wang R; Griffiths S; Li H; Peister A; Copland I; McDevitt T
    J Vasc Surg; 2017 Mar; 65(3):826-838.e1. PubMed ID: 26921003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy.
    Nammian P; Asadi-Yousefabad SL; Daneshi S; Sheikhha MH; Tabei SMB; Razban V
    Stem Cell Res Ther; 2021 Jan; 12(1):58. PubMed ID: 33436054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells.
    Arango-Rodríguez ML; Mateus LC; Sossa CL; Becerra-Bayona SM; Solarte-David VA; Ochoa Vera ME; Viviescas LTG; Berrio AMV; Serrano SE; Vargas O; Isla AC; Benitez A; Rangel G
    Stem Cell Res Ther; 2023 Aug; 14(1):221. PubMed ID: 37626416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia.
    Powell RJ; Comerota AJ; Berceli SA; Guzman R; Henry TD; Tzeng E; Velazquez O; Marston WA; Bartel RL; Longcore A; Stern T; Watling S
    J Vasc Surg; 2011 Oct; 54(4):1032-41. PubMed ID: 21684715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia.
    Madaric J; Klepanec A; Valachovicova M; Mistrik M; Bucova M; Olejarova I; Necpal R; Madaricova T; Paulis L; Vulev I
    Stem Cell Res Ther; 2016 Aug; 7(1):116. PubMed ID: 27530339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls.
    Gremmels H; Teraa M; Quax PH; den Ouden K; Fledderus JO; Verhaar MC
    Mol Ther; 2014 Nov; 22(11):1960-70. PubMed ID: 25174586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI).
    Shirbaghaee Z; Heidari Keshel S; Rasouli M; Valizadeh M; Hashemi Nazari SS; Hassani M; Soleimani M
    Stem Cell Res Ther; 2023 Jul; 14(1):174. PubMed ID: 37408043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human bone marrow-derived, pooled, allogeneic mesenchymal stromal cells manufactured from multiple donors at different times show comparable biological functions in vitro, and in vivo to repair limb ischemia.
    Thej C; Balasubramanian S; Rengasamy M; Walvekar A; Swamynathan P; Raj SS; Shahani P; Siddikuzzaman ; Kolkundkar U; Seetharam RN; Gupta PK; Majumdar AS
    Stem Cell Res Ther; 2021 May; 12(1):279. PubMed ID: 33971964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of autologous transplantation of bone marrow stem cells for critical limb ischemia: results of the Naples and Pietra Ligure Evaluation of Stem Cells study.
    Schiavetta A; Maione C; Botti C; Marino G; Lillo S; Garrone A; Lanza L; Pagliari S; Silvestroni A; Signoriello G; Sica V; Cobellis G
    Stem Cells Transl Med; 2012 Jul; 1(7):572-8. PubMed ID: 23197862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia.
    Iafrati MD; Hallett JW; Geils G; Pearl G; Lumsden A; Peden E; Bandyk D; Vijayaraghava KS; Radhakrishnan R; Ascher E; Hingorani A; Roddy S
    J Vasc Surg; 2011 Dec; 54(6):1650-8. PubMed ID: 22019148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI).
    Amann B; Lüdemann C; Rückert R; Lawall H; Liesenfeld B; Schneider M; Schmidt-Lucke J
    Vasa; 2008 Nov; 37(4):319-25. PubMed ID: 19003741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Autologous Cell-based Therapy in Patients with No-option Critical Limb Ischaemia: A Meta-Analysis.
    Wahid FSA; Ismail NA; Wan Jamaludin WF; Muhamad NA; Mohamad Idris MA; Lai NM
    Curr Stem Cell Res Ther; 2018; 13(4):265-283. PubMed ID: 29532760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Therapeutic Angiogenesis Using Autologous Bone Marrow-derived Mononuclear Cell Implantation in Patients with No-option Critical Limb Ischemia.
    Yanishi K; Shoji K; Fujioka A; Hori Y; Yukawa A; Matoba S
    Ann Vasc Dis; 2020 Mar; 13(1):13-22. PubMed ID: 32273917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia.
    Wang SK; Green LA; Motaganahalli RL; Wilson MG; Fajardo A; Murphy MP
    J Vasc Surg; 2017 Jun; 65(6):1850-1857.e2. PubMed ID: 28390770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of mesenchymal stem cells of "no-options" patients with critical limb ischemia treated by autologous bone marrow mononuclear cells.
    Altaner C; Altanerova V; Cihova M; Hunakova L; Kaiserova K; Klepanec A; Vulev I; Madaric J
    PLoS One; 2013; 8(9):e73722. PubMed ID: 24069226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone healing capacity in patients undergoing total hip arthroplasty].
    Kučera T; Soukup T; Krs O; Urban K; Sponer P
    Acta Chir Orthop Traumatol Cech; 2012; 79(1):52-8. PubMed ID: 22405550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia.
    Wijnand JGJ; Teraa M; Gremmels H; van Rhijn-Brouwer FCC; de Borst GJ; Verhaar MC;
    J Vasc Surg; 2018 Feb; 67(2):656-661. PubMed ID: 29242062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Therapeutic Angiogenesis Using Autologous Bone Marrow-Derived Mononuclear Cells Implantation in Critical Limb Ischemia With Scleroderma　- Subanalysis of the Long-Term Clinical Outcomes Survey.
    Shoji K; Yanishi K; Yoshimi R; Hamada N; Kondo K; Fujimoto K; Nakajima H; Kuwahara K; Higashi Y; Fukumoto Y; Murohara T; Matoba S;
    Circ J; 2019 Feb; 83(3):662-671. PubMed ID: 30726805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.